Table 1.

Baseline characteristics of children who received darunavir in the CHAPAS-4 trial, stratified by NRTI backbone

		Total (N = 59)	TAF/FTC (N = 34)	ABC/3TC (N = 12)	ZDV/3TC (N = 13)
Age (years)	Median [min–max]	10.9 [3.8–14.7]	10.9 [3.8–14.7]	12.5 [6.9–14.3]	9.5 [3.9–12.9]
Sex: n (%)
Female		33 (55.9%)	18 (52.9%)	7 (58.3%)	8 (61.5%)
Male		26 (44.1%)	16 (47.1%)	5 (41.7%)	5 (38.5%)
Weight (kg)	Median [min–max]	26.0 [14.5–47.0]	24.0 [14.5–47.0]	31.7 [19.2–45.8]	22.4 [16.5–44.0]
Weight band (kg): n (%)
14–19.9		12 (20.3%)	7 (20.6%)	1 (8.3%)	4 (30.8%)
20–24.9		17 (28.8%)	11 (32.4%)	1 (8.3%)	5 (38.5%)
25–34.9		17 (28.8%)	9 (26.5%)	6 (50.0%)	2 (15.4%)
≥35		13 (22.0%)	7 (20.6%)	4 (33.3%)	2 (15.4%)
Height (cm)	Median [min–max]	132 [97.8–161]	133 [97.8–161]	142 [113–156]	126 [101–144]
Darunavir dose (mg/kg)	Median [min–max]	26.7 [17.0–41.4]	26.5 [17.0–41.4]	25.2 [17.5–31.3]	28.6 [18.2–36.4]
Ritonavir dose (mg/kg)	Median [min–max]	3.85 [2.13–6.90]	4.17 [2.13–6.90]	3.16 [2.18–5.21]	4.46 [2.27–6.06]
AAG (g/L)	Median [min–max]	0.7 [0.3–1.9]	0.7 [0.3–1.5]	0.6 [0.3–1.1]	0.7 [0.4–1.9]

TAF/FTC, tenofovir alafenamide/emtricitabine; ABC/3TC, abacavir/lamivudine, ZDV/3TC, zidovudine/lamivudine.